GPGiulia Perilli

Giulia Perilli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giulia Perilli has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DNA-decorated phase-shift microdroplets enable programmable coalescence and gene transfection

    by Giulia Perilli, Angela Ditri, Alessandra Vitaliti, Yosra Toumia, Alessandro Porchetta, Gaio Paradossi, Fabio Domenici

    Hypothesis. Phase-shift perfluorocarbon microdroplets (MDs) are a promising and flexible method for challenging applications in colloid science, such as customizing chemical reactions or enhancing tumor gene delivery efficiency. To achieve these goals, we focused on stable MDs made of a decafluoropentane core and a dimethyldioctadecylammonium bromide (DDAB) lipid shell that binds DNA through electrostatic interactions to create DNA-MDs assemblies.Experimental. The MDs were obtained via ultrasound homogenization and decorated with complementary DNAs. Fluorescence, confocal microscopy, and dynamic light scattering methodologies were combined to measure the binding features driving DNA-MDs formation and their coalescing interactions. The effect of the DNA-MDs at the cell interface was evaluated by MTT viability assay and DNA transfection in tumor melanoma cells.Findings. We defined the colloidal formulation of DNA-MDs, functional for both chemical and biomedical relevant applications. First, we identified the conditions that enable DNA-MDs to rapidly and selectively coalesce via oligonucleotide hybridization at the MDs interface. Then, we used DNA-MDs to efficiently enter nucleic acids into human melanoma cells, even within a two-step transfection protocol to promote intracellular DNA strand displacement.Our results could shed new light on conducting controlled reactions in small volumes, realizing microreactors, as well as designing consensus gene transfection strategies.

  • Open Access

    Intra-Arterial Super-Selective Delivery of Yttrium-90 for the Treatment of Recurrent Glioblastoma: In Silico Proof of Concept with Feasibility and Safety Analysis

    by Giulia Paolani, Silvia Minosse, Silvia Strolin, Miriam Santoro, Noemi Pucci, Francesca Di Giuliano, Francesco Garaci, Letizia Oddo, Yosra Toumia, Eugenia Guida, et al.

    Background: Intra-arterial cerebral infusion (IACI) of radiotherapeutics is a promising treatment for glioblastoma (GBM) recurrence. We investigated the in silico feasibility and safety of Yttrium-90-Poly(vinyl alcohol)-Microbubble (90Y-PVA-MB) IACI in patients with recurrent GBM and compared the results with those of external beam radiation therapy (EBRT). Methods: Contrast-enhanced T1-weighted magnetic resonance imaging (T1W-MRI) was used to delineate the tumor volumes and CT scans were used to automatically segment the organs at risk in nine patients with recurrent GBM. Volumetric Modulated Arc Therapy (VMAT) treatment plans were generated using a clinical treatment planning system. Assuming the relative intensity of each voxel from the MR-T1W as a valid surrogate for the post-IACI 90Y-PVA-MB distribution, a specific 90Y dose voxel kernel was obtained through Monte Carlo (MC) simulations and convolved with the MRI, resulting in a 90Y-PVA-MB-based dose distribution that was then compared with the VMAT plans. Results: The physical dose distribution obtained from the simulation of 1GBq of 90Y-PVA-MBs was rescaled to ensure that 95% of the prescribed dose was delivered to 95% or 99% of the target (i.e., A95% and A99%, respectively). The calculated activities were A95% = 269.2 [63.6–2334.1] MBq and A99% = 370.6 [93.8–3315.2] MBq, while the mean doses to the target were 58.2 [58.0–60.0] Gy for VMAT, and 123.1 [106.9–153.9] Gy and 170.1 [145.9–223.8] Gy for A95% and A99%, respectively. Additionally, non-target brain tissue was spared in the 90Y-PVA-MB treatment compared to the VMAT approach, with a median [range] of mean doses of 12.5 [12.0–23.0] Gy for VMAT, and 0.6 [0.2–1.0] Gy and 0.9 [0.3–1.5] Gy for the 90Y treatments assuming A95% and A99%, respectively. Conclusions: 90Y-PVA-MB IACI using MR-T1W appears to be feasible and safe, as it enables the delivery of higher doses to tumors and lower doses to non-target volumes compared to the VMAT approach.